Clinical trial
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial…
NCT00093626 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00093626 |
|---|---|
| Title | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer |
| Official title | A Phase II Evaluation of BAY 43-9006 (Sorafenib, Nexavar®, NCI-Supplied Agent, NSC #724772) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma |
| Intervention type | Drug, Other |
| Interventions | Laboratory Biomarker Analysis, Sorafenib Tosylate |
| Enrollment | 73 |
| Start date | Oct 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Jan 1, 2011 |
| First posted | Oct 8, 2004 |
| Last update posted | Jul 23, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: